Centessa Pharmaceuticals' GC Hussain Iqbal J buys, sells 6,000 shares on 2025-08-15.

Centessa Pharmaceuticals plc (CNTA) has recently announced that General Counsel Hussain Iqbal J has acquired 6,000 shares at a price of $5.84 per share on August 15, 2025. Additionally, it has been reported that Hussain Iqbal J sold 6,000 shares at a price of $17.23 per share on the same date.

Centessa Pharmaceuticals plc (CNTA) has recently reported that General Counsel Hussain Iqbal J has executed significant share transactions on August 15, 2025. The transactions involved the acquisition and subsequent sale of 6,000 ordinary shares.

On the same date, Hussain Iqbal J exercised an option to acquire 6,000 ordinary shares at an exercise price of $5.84 per share, totaling $35,040. Immediately following the option exercise, he sold 6,000 ordinary shares at a price of $17.23 per share, totaling $103,380. The sale was executed under a Rule 10b5-1 trading plan adopted on September 14, 2024 [1].

Following the transactions, Hussain Iqbal J directly owns 105,386 ordinary shares, with an additional 5,500 shares indirectly held by his spouse. The transactions occurred while Centessa’s stock was trading near its 52-week high of $19.09, with the company’s market capitalization reaching $2.37 billion [2].

The stock has delivered a strong 37.9% return over the past year, though technical indicators suggest the stock is currently in overbought territory [1]. The company’s recent developments, including analyst ratings and corporate appointments, have drawn significant investor interest. Truist Securities initiated coverage on Centessa with a Buy rating and a $30.00 price target, while Piper Sandler maintained an Overweight rating with a $38.00 price target [1].

In corporate news, Centessa announced the appointment of Raphael Deferiere as the new Chief Accounting Officer, effective May 27, 2025. Deferiere brings substantial experience from his role as an Assurance Partner at Ernst & Young [1]. Investors are keeping an eye on upcoming data readouts from the Phase 2 CRYSTAL-1 study, expected in 2025.

The insider transactions reported by Hussain Iqbal J are consistent with the company’s disclosure norms and align with Section 16 requirements and 10b5-1 safe-harbor usage [3]. The filing provides transparent disclosure of insider ownership and the use of a pre-existing trading plan, reducing concerns about opportunistic insider trading.

References:
[1] https://www.investing.com/news/insider-trading-news/centessa-pharma-general-counsel-sells-103k-in-shares-93CH-4196354
[2] https://www.tradingview.com/news/tradingview:bf08539b7852f:0-centessa-pharmaceuticals-officer-sells-shares/
[3] https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-american-insider-trading-activity-820a40705d6c.html